Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Lonsway is active.

Publication


Featured researches published by David Lonsway.


Journal of Clinical Microbiology | 2008

Characterization of Staphylococcus aureus Isolates from Nasal Cultures Collected from Individuals in the United States in 2001 to 2004

Fred C. Tenover; Sigrid K. McAllister; Gregory E. Fosheim; Linda K. McDougal; Roberta B. Carey; Brandi Limbago; David Lonsway; Jean B. Patel; Matthew J. Kuehnert; Rachel J. Gorwitz

ABSTRACT This study characterizes methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) isolates recovered from nasal cultures of noninstitutionalized individuals in the United States obtained in 2001 to 2004 as part of the National Health and Nutrition Examination Survey. Every tenth MSSA isolate and all MRSA isolates were typed by pulsed-field gel electrophoresis (PFGE), screened for multiple toxin genes, and tested for susceptibility to 14 antimicrobial agents. USA200, USA600, and USA900 were the predominant PFGE types among MSSA isolates in both the 2001 to 2002 and the 2003 to 2004 time periods, although they accounted for only 51.3% of 316 MSSA isolates typed in 2001 and 2002 and only 43.4% of 237 MSSA isolates typed in 2003 and 2004. In contrast, USA100, USA800, and USA700 accounted for 80.0% of the 75 MRSA isolates typed in 2001 and 2002, while USA100, USA800, and USA300 accounted for 78.4% of 134 MRSA isolates typed in 2003 and 2004. The proportion of MRSA isolates that were USA300 increased significantly from the first to the second time period (P = 0.03). Most USA200 isolates (both MSSA and MRSA) carried the gene for toxic shock syndrome toxin; however, carriage of the genes encoding Panton-Valentine leukocidin, while common among MRSA of PFGE type USA300, was rare among MSSA USA300 in both time periods. Most MSSA isolates remained susceptible to all antimicrobial agents except erythromycin (79.1 and 76.0% susceptibilities in the 2001 to 2002 and the 2003 to 2004 periods, respectively). In contrast, the proportions of MRSA isolates that were susceptible to chloramphenicol, clindamycin, and erythromycin were lower in 2003 and 2004 than in 2001 and 2002, although none of these differences was statistically significant.


Morbidity and Mortality Weekly Report | 2015

Notes from the Field: Carbapenem-resistant Enterobacteriaceae Producing OXA-48-like Carbapenemases--United States, 2010-2015.

Meghan Lyman; Maroya Spalding Walters; David Lonsway; Kamile Rasheed; Brandi Limbago

Carbapenem-resistant Enterobacteriaceae (CRE) are bacteria that are often resistant to most classes of antibiotics and cause health care-associated infections with high mortality rates. Among CRE, strains that carry plasmid-encoded carbapenemase enzymes that inactivate carbapenem antibiotics are of greatest public health concern because of their potential for rapid global dissemination, as evidenced by the increasing distribution of CRE that produce the Klebsiella pneumoniae carbapenemase and the New Delhi metallo-β-lactamase. Newly described resistance in Enterobacteriaceae, such as plasmid-mediated resistance to the last-line antimicrobial colistin, recently detected in China, and resistance to the newly approved antimicrobial, ceftazidime-avibactam, identified from a U.S. K. pneumoniae carbapenemase-producing isolate, highlight the continued urgency to delay spread of CRE. Monitoring the emergence of carbapenemases is crucial to limiting their spread; identification of patients carrying carbapenemase-producing CRE should result in the institution of transmission-based precautions and enhanced environmental cleaning to prevent transmission.* The OXA-48 carbapenemase was first identified in Enterobacteriaceae in Turkey in 2001, and OXA-48-like variants have subsequently been reported around the world. The first U.S. reports of OXA-48-like carbapenemases were published in 2013 and included retrospectively identified isolates from 2009 and two isolates collected in 2012 from patients in Virginia who had recently been hospitalized outside the United States. Although there are limited additional published reports from the United States, CDC continues to receive reprots of these organisms. This report describes patients identified as carrying CRE producing OXA-48-like carbapenemases in the United States during June 2010-August 2015.


Morbidity and Mortality Weekly Report | 2015

Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015.

Maroya Spalding Walters; Paula Eggers; Valerie Albrecht; Tatiana Travis; David Lonsway; Greg Hovan; Debra Taylor; Kamile Rasheed; Brandi Limbago

Vancomycin-resistant Staphylococcus aureus (VRSA) is a rare, multidrug-resistant bacterium of public health concern that emerged in the United States in 2002. VRSA (S. aureus with vancomycin minimum inhibitory concentration [MIC] ≥16 μg/mL) arises when vancomycin resistance genes (e.g., the vanA operon, which codes for enzymes that result in modification or elimination of the vancomycin binding site) from vancomycin-resistant enterococci (VRE) are transferred to S. aureus (1). To date, all VRSA strains have arisen from methicillin-resistant S. aureus (MRSA). The fourteenth VRSA isolate (VRSA 14) identified in the United States was reported to CDC in February 2015.


Emerging Infectious Diseases | 2018

Phenotypic and Genotypic Characterization of Enterobacteriaceae Producing Oxacillinase-48–Like Carbapenemases, United States

Joseph D. Lutgring; Wenming Zhu; Tom J. B. de Man; Johannetsy J. Avillan; Karen F. Anderson; David Lonsway; Lori A. Rowe; Dhwani Batra; J. Kamile Rasheed; Brandi Limbago

Oxacillinase (OXA)–48–like carbapenemases remain relatively uncommon in the United States. We performed phenotypic and genotypic characterization of 30 Enterobacteriaceae producing OXA-48–like carbapenemases that were recovered from patients during 2010–2014. Isolates were collected from 12 states and not associated with outbreaks, although we could not exclude limited local transmission. The alleles β-lactamase OXA-181 (blaOXA-181) (43%), blaOXA-232 (33%), and blaOXA-48 (23%) were found. All isolates were resistant to ertapenem and showed positive results for the ertapenem and meropenem modified Hodge test and the modified carbapenem inactivation method; 73% showed a positive result for the Carba Nordmann–Poirel test. Whole-genome sequencing identified extended-spectrum β-lactamase genes in 93% of isolates. In all blaOXA-232 isolates, the gene was on a ColKP3 plasmid. A total of 12 of 13 isolates harboring blaOXA-181 contained the insertion sequence ΔISEcp1. In all isolates with blaOXA-48, the gene was located on a TN1999 transposon; these isolates also carried IncL/M plasmids.


Journal of Clinical Microbiology | 2010

Effect of Carbon Dioxide on Broth Microdilution Susceptibility Testing of Brucella spp.

David Lonsway; Laura A. Jevitt; James R. Uhl; Franklin R. Cockerill; Mary E. Anderson; Maureen Sullivan; Barun K. De; Jonathan R. Edwards; Jean B. Patel

ABSTRACT Since some strains of Brucella species may require carbon dioxide for growth, a multilaboratory study was conducted to compare broth microdilution susceptibility results using ambient air (AA) and 5% CO2 incubation conditions. Six antimicrobial agents were tested against 39 Brucella isolates. Aminoglycoside MICs tended to be 1 log2 dilution higher in CO2 than in AA; tetracycline-class MICs to be 1 log2 dilution lower in CO2.


Infection Control and Hospital Epidemiology | 2018

Hospital microbiology laboratory practices for Enterobacteriaceae: Centers for Disease Control and Prevention National Healthcare Safety Network (NHSN) annual survey, 2015 and 2016

Alicia Shugart; Maroya Spalding Walters; Lindsey M. Weiner; David Lonsway

We analyzed clinical microbiology laboratory practices for detection of multidrug-resistant Enterobacteriaceae in US short-stay acute-care hospitals using data from the National Healthcare Safety Network (NHSN) Annual Facility Survey. Half of hospitals reported testing for carbapenemases, and 1% performed routine polymyxin susceptibility testing using reference broth microdilution.


The New England Journal of Medicine | 2005

A clone of methicillin-resistant Staphylococcus aureus among professional football players

Sophia V. Kazakova; Jeffrey C. Hageman; Matthew J. Matava; Arjun Srinivasan; Larry Phelan; Bernard Garfinkel; Thomas Boo; Sigrid K. McAllister; James R. Anderson; Bette Jensen; Doug Dodson; David Lonsway; Linda K. McDougal; Matthew J. Arduino; Victoria J. Fraser; George Killgore; Fred C. Tenover; Sara Cody; Daniel B. Jernigan


Journal of Infection | 2007

Emergence of community-associated methicillin resistant Staphylococcus aureus in Hawaii, 2001–2003

Concepcion F. Estivariz; Sarah Y. Park; Jeffrey C. Hageman; Jeffrey D. Dvorin; Marian Melish; Rose Arpon; Pat Coon; Susan Slavish; Mary Kim; Linda K. McDougal; Bette Jensen; Sigrid K. McAllister; David Lonsway; George Killgore; Paul Effler; Daniel Jernigan


Open Forum Infectious Diseases | 2017

Mcr-1 in Connecticut: Investigations of an Emerging Resistance Gene in Two Patients, 2016–2017

Vivian Leung; Noelisa Montero; Meghan Maloney; Amber Vasquez; Mark Laughlin; Ehren Dancy; Russell Melmed; Jessica Chen; Jason P. Folster; Rebecca L. Lindsey; David Lonsway; Sandra Boyd; Louise Francois Watkins; Maroya Spalding Walters; Lynn Sosa


Archive | 2017

The Modified Carbapenem Inactivation Method (mCIM) for Phenotypic Detection of Carbapenemase Production among .

Virginia M. Pierce; Patricia J. Simner; David Lonsway; Darcie E. Roe-Carpenter; J. Kristie Johnson; William B. Brasso; April M. Bobenchik; Zabrina C. Lockett; Angella Charnot-Katsikas; Mary Jane Ferraro; Richard B. Thomson; Stephen G. Jenkins; Brandi Limbago; Sanchita Das

Collaboration


Dive into the David Lonsway's collaboration.

Top Co-Authors

Avatar

Brandi Limbago

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Maroya Spalding Walters

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Linda K. McDougal

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Sigrid K. McAllister

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Bette Jensen

United States Department of Health and Human Services

View shared research outputs
Top Co-Authors

Avatar

Fred C. Tenover

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

George Killgore

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jean B. Patel

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jeffrey C. Hageman

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Alicia Shugart

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge